Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary) ; Bendamustine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms Tugela
- Sponsors Gilead Sciences
- 26 Jun 2019 Status changed from active, no longer recruiting to completed.
- 25 Jun 2019 This trial has been completed in Belgium, according to European Clinical Trials Database.
- 06 May 2019 Planned End Date changed from 1 Mar 2019 to 1 May 2019.